Navigation Links
GenWay Biotech Appoints New Vice President of Custom/OEM
Date:5/1/2012

SAN DIEGO, May 1, 2012 /PRNewswire-iReach/ -- GenWay Biotech today announced the appointment of Mark Fitchmun as the company's new Vice President of GenWay Custom/OEM. This position was created as part of GenWay Biotech's efforts to focus on growth of the individual divisions including GenWay Custom/OEM, GenWay Catalog, and FirstMark Diagnostics. Since 1998, GenWay Biotech has provided the diagnostic and research communities with thousands specialty reagents and assays with unmatched quality workmanship at affordable prices. The company is recognized as a trusted out-sourcing partner throughout the world.

"GenWay leads the industry in product quality and customer satisfaction. We are truly proud of our reputation, and grateful for our customer's trust and support. Our customer's success, and contribution to our shareholders return on investment are the driving factors behind GenWay, and we are leveraging this success for our growth plans," stated Thomas Silberg, President and CEO of GenWay Biotech. "Mark's dedication to customer satisfaction, and his extensive experience in the biopharmaceutical industry developing and implementing robust manufacturing processes and assays, will be integral to GenWay Biotech's growth plans. We look forward to having him apply those same skills at GenWay."

As Vice President of GenWay Custom/OEM division, Fitchmun's primary role will be to lead the strategic direction for growth and day-to-day activities for the division. Fitchmun's 25 years of leadership and technical experience in the biopharmaceutical industry has ranged from small entrepreneurial biotech startups, to large established equipment and pharmaceutical companies. Since 1992, Fitchmun served as Principal for Somateck, Inc., where he provided development, manufacturing, and project management support to companies creating next generation biopharmaceuticals, diagnostics, research reagents, and kits for domestic and international clients. He has also held positions at biotech companies such a GenStar Therapeutics, Demos, Hygeia and Bio-Rad.

Fitchmun's unique qualifications will allow him to direct the expansion of the expertise, knowledge and technologies owned by GenWay, and to drive the development of cutting-edge enabling technologies to deliver faster, more reliable and cost-effective services and products than competitors.  "GenWay is in an excellent position to grow the Custom/OEM division. Our talented team of scientists and technicians provide the utmost quality for custom reagent development, assay development and qualification for our clients in the pharmaceutical and diagnostics industry, " said Fitchmun. "I look forward to leading this impressive team, winning new contracts, and maintaining the highest level of service to enable the productivity of GenWay's clients."  

About GenWay Biotech
FirstMark is a division of GenWay Biotech, Inc. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. Headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area. For additional information please visit GenWayBio.com.

About GenWay Biotech, Inc.
GenWay Biotech, is comprised of three divisions. GenWay's  catalog products and custom services divisions are focused on protein and antibody solu­tions. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. GenWay's headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area. For additional information, please visit GenWayBio.com.

6777 Nancy Ridge Drive, San Diego, CA 92121     |     P: 858.458.0866     |     F: 858.458.0833

Media Contact: Deborah Moore GenWay Biotech, 858-458-0866, dmoore@genwaybio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE GenWay Biotech
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
4. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
5. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
6. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
7. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
8. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
9. Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials
10. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
11. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... today announced that the Company,s first quarter 2017 financial ... May 11, 2017, and that the Company will host ... PT that afternoon. Management will provide an overview of ...
(Date:5/3/2017)... , May 3, 2017  Kalorama Information ... of nine percent next year and this is ... and hematopoietic stem cell (HSCT) or bone marrow ... testing technologies are well-suited for this task. This ... research publisher Kalorama Information. The various PCR-based methodologies, ...
(Date:5/3/2017)... May 3, 2017  West Pharmaceutical Services, Inc. ... for injectable drug administration, announced today that ... Technical Services, and Diane Paskiet , Director, ... presentations focused on West,s expertise in the areas ... well as providing commentary on updated industry guidance. ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... 24, 2017 , ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is ... without a referral. Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can ... OH. Patients no longer need to feel the esthetic effects of wires and brackets ...
(Date:5/24/2017)... Birmingham, Clarkston, Lake Orion, Michigan (PRWEB) , ... ... ... Endometriosis is a disease affecting the female reproductive tract in which ... itself on the pelvic structures causing inflammation and pain. Patients experiencing painful ...
(Date:5/24/2017)... ... 24, 2017 , ... Rob Lowe is a sought after actor, and also ... brings the public important topics from all aspects of life, and a new segment ... surrounding feet and ankles. , Podiatry is essential to people’s overall well-being, and if ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a leading ... that its iClinic V12.2 solution has achieved approval from National Center for Quality ... 2017 standards which emphasize team-based care with a significant focus on the care ...
(Date:5/23/2017)... ... ... New England Journal Of Medicine Confirms Viability of Rory’s Regulations and Deems ... Foundation Calls on Health & Human Services, Tom Price to Adopt Rory’s Regulations Nationally- ... reported on a new study released on May 21, 2017 in the New England ...
Breaking Medicine News(10 mins):